Systemic Juvenile Idiopathic Arthritis Clinical Trial
Official title:
An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With sJIA Who Participated in Studies MRA011JP or MRA316JP
An open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with sJIA who were participated in Studies MRA011JP or MRA316JP
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00891046 -
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
|
Phase 3 | |
Completed |
NCT01304420 -
Ultrasonography in Juvenile Idiopathic Arthritis
|
Phase 0 | |
Completed |
NCT02334748 -
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
|
Phase 3 | |
Completed |
NCT01803321 -
Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 1 | |
Completed |
NCT00144664 -
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
|
Phase 3 | |
Completed |
NCT02396212 -
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
|
Phase 3 | |
Completed |
NCT00144599 -
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 3 | |
Terminated |
NCT00886769 -
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
|
Phase 3 | |
Withdrawn |
NCT01676948 -
An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
|
Phase 3 | |
Recruiting |
NCT04088396 -
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
|
Phase 3 | |
Recruiting |
NCT05027373 -
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
|
Phase 1 |